Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database
-
Published:2024-03-13
Issue:1
Volume:22
Page:
-
ISSN:1477-7525
-
Container-title:Health and Quality of Life Outcomes
-
language:en
-
Short-container-title:Health Qual Life Outcomes
Author:
Dixit Jyoti,Gupta Nidhi,Kataki Amal,Roy Partha,Mehra Nikita,Kumar Lalit,Singh Ashish,Malhotra Pankaj,Gupta Dharna,Goyal Aarti,Rajsekar Kavitha,Krishnamurthy Manjunath Nookala,Gupta Sudeep,Prinja Shankar
Abstract
Abstract
Background
Cancer survivors experience a decrement in health-related quality of life (HRQoL) resulting from the disease as well as adverse effects of therapy. We evaluated the HRQoL of cancer patients, stratified by primary cancer site, stage, treatment response and associated adverse events, along with its determinants.
Methods
Data were collected from 12,148 patients, sampled from seven purposively chosen leading cancer hospitals in India, to elicit HRQoL using the EuroQol questionnaire comprising of 5-dimensions and 5-levels (EQ-5D-5L). Multiple linear regression was used to determine the association between HRQoL and various socio-demographic as well as clinical characteristics.
Results
Majority outpatients (78.4%) and inpatients (81.2%) had solid cancers. The disease was found to be more prevalent among outpatients (37.5%) and inpatients (40.5%) aged 45–60 years and females (49.3–58.3%). Most patients were found to be in stage III (40–40.6%) or stage IV (29.4–37.3%) at the time of recruitment. The mean EQ-5D-5 L utility score was significantly higher among outpatients [0.630 (95% CI: 0.623, 0.637)] as compared to inpatients [0.553 (95% CI: 0.539, 0.567)]. The HRQoL decreased with advancing cancer stage among both inpatients and outpatients, respectively [stage IV: (0.516 & 0.557); stage III (0.609 & 0.689); stage II (0.677 & 0.713); stage I (0.638 & 0.748), p value < 0.001]. The outpatients on hormone therapy (B = 0.076) showed significantly better HRQoL in comparison to patients on chemotherapy. However, palliative care (B=-0.137) and surgery (B=-0.110) were found to be associated with significantly with poorer HRQoL paralleled to chemotherapy. The utility scores among outpatients ranged from 0.305 (bone cancer) to 0.782 (Leukemia). Among hospitalized cases, the utility score was lowest for multiple myeloma (0.255) and highest for testicular cancer (0.771).
Conclusion
Older age, lower educational status, chemotherapy, palliative care and surgery, advanced cancer stage and progressive disease were associated with poor HRQoL. Our study findings will be useful in optimising patient care, formulating individualized treatment plan, improving compliance and follow-up.
Funder
Department of Health Research, Ministry of Health and Family Welfare, New Delhi
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30. 2. World Health Organization (WHO). (2020) Global Health Estimates 2020 deaths by cause, age, sex, by country and by region, 2000–2019. World Health Organization, Geneva. - references - scientific research publishing. 2022 [cited 2022 Aug 7]. Available from: https://www.scirp.org/reference/referencespapers.aspx?referenceid=3188789. 3. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53. 4. Sharma S. Fighting cancer with cheap treatment and screening. Hindustan Times, New Delhi. 2018 Sep 23 [cited 2022 August 7]. Available from: https://www.hindustantimes.com/health/fighting-cancer-with-cheap-treatment-and-screening/story-GbPF7x8Nb6Z15TWurEppNK.html. 5. Mallath MK, Taylor DG, Badwe RA, Rath GK, Shanta V, Pramesh CS, Digumarti R, Sebastian P, Borthakur BB, Kalwar A, Kapoor S. The growing burden of cancer in India: epidemiology and social context. Lancet Oncol. 2014;15(6):e205–12.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|